Christine M. Ryu-Naya

Christine Ryu-Naya is an experienced antitrust lawyer whose practice focuses on U.S. and international merger clearance, counseling, investigations, and antitrust litigation. She has counseled clients through all stages of the merger review process, including representing parties before the Department of Justice and Federal Trade Commission in connection with complex and vigorously challenged transactions, negotiating and complying with government information requests, coordinating antitrust filings in foreign jurisdictions, and negotiating and implementing consent orders.

Ms. Ryu-Naya counsels clients on a variety of business issues, including interlocking directorates, data privacy, integration planning, non-solicitation agreements, and the design and implementation of compliance programs. Her practice also includes representing companies in internal competition-related investigations and in connection with investigations launched by federal antitrust enforcement agencies. She has helped with favorable business outcomes and motions to dismiss for corporations facing complex and contentious litigation matters in federal district court.

Prior to joining Baker Botts, Ms. Ryu-Naya was an associate at another large international law firm.

• Represented Merck & Co. in its acquisitions of OncoImmune and ArQule, as well as various potential acquisitions.
• Represented leading mid-market private equity fund, American Industrial Partners, in connection with its acquisitions of Moly-Cop, Goss International, and numerous other businesses.
• Represented defendant, Eaton Corporation, in complaint action alleging monopolization, exclusionary conduct, fraud, unfair competition, and unjust enrichment brought by an indirect purchaser in federal court in Missouri.
• Represented Boehringer Ingelheim in its $12.6 billion asset swap with Sanofi.
• Represented Rockwater Energy Solutions in its merger with Select Energy Solutions.
• Represented private company client in negotiating an FTC Part III administrative proceeding.
• Represented MeadWestvaco Corporation in receiving worldwide clearance for its $16 billion merger with RockTenn Corporation.
• Represented Novartis in its $20 billion oncology and vaccines transaction with GlaxoSmithKline.

Recognized by Washington D.C. Super Lawyers as a "Rising Star," 2019 & 2020

Recognized in Best Lawyers' Inaugural "Ones to Watch" List, 2020